Amyloidosis, Hereditary
Information
- Disease name
- Amyloidosis, Hereditary
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03759379 | Active, not recruiting | Phase 3 | HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) | February 14, 2019 | October 2026 |
| NCT03400098 | Approved for marketing | ATTR Expanded Access Program (EAP) by Ionis | |||
| NCT02939820 | Approved for marketing | Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR) | |||
| NCT01960348 | Completed | Phase 3 | APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis | November 2013 | August 2017 |
| NCT02319005 | Completed | Phase 3 | ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) | December 2014 | March 30, 2017 |
| NCT05974644 | Not yet recruiting | Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry | September 1, 2024 | December 1, 2030 | |
| NCT05489549 | Recruiting | Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers | November 21, 2022 | June 30, 2027 | |
| NCT05873868 | Recruiting | Myocardial Effects in Patients With ATTRv With Polyneuropathy Treated With Patisiran or Vutrisiran | April 12, 2024 | July 2026 | |
| NCT05879874 | Recruiting | Prospective Evaluation of NfL as a Biomarker in ATTRv | September 1, 2023 | June 2026 |